OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study
B E Sands(Icahn School of Medicine at Mount Sinai), Julián Panés(Hospital Clínic de Barcelona), Martha Marko(McMaster University), Brian G. Feagan(Western University), Nicole Shipitofsky(Janssen (United States)), M Vetter(Janssen (United States)), S. Sheng(Janssen (United States)), Matthew Germinaro(Johnson & Johnson (United States)), Jewel Johanns(Johnson & Johnson (United States)), William J. Sandborn(University of San Diego)
Cited by 33
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k